Contents
Cervical cancer on the OB-GYN shelf is mostly a screening topic. A question gives an age, a test result and sometimes a pregnancy, and asks what happens next: routine screening, a repeat test, colposcopy or treatment. Staging appears less often, usually as one finding (hydronephrosis, parametrial spread) that sets the stage.
The screening timeline
For average-risk patients with a cervix, following ACOG guidance updated in 2026.
- Under 21: no screeningRegardless of sexual activity. HPV infection at this age usually clears.
- 21 to 29: cytology every 3 yearsHPV testing is not used for routine screening under 30 in this schedule. The American Cancer Society instead starts at 25 with primary HPV testing every 5 years.
- 30 to 65: primary high-risk HPV testing every 5 years, preferredClinician-collected samples are preferred. Self-collected vaginal HPV testing with an FDA-approved device is an acceptable option; after a negative self-collected test, ACS and the Enduring Consensus guidelines repeat in 3 years. Cotesting every 5 years or cytology every 3 years remains acceptable.
- Over 65: stop after adequate negative screeningACS now asks for negative HPV-based tests at 60 and 65 before exit. Patients with a history of CIN2 or worse continue for at least 25 years after treatment.
- After hysterectomy: usually stopIf the cervix was removed for a benign reason and there is no history of CIN2 or worse, screening ends.
Sources differ on the details: the USPSTF's December 2024 draft also prefers primary HPV testing from 30 to 65 and includes self-collection, but on a 5-year interval. Exams follow the core schedule above, which all groups share.
HPV vaccination
- Routine at 11 to 12 years; it can start at 9.
- Catch-up through 26 years for anyone not adequately vaccinated.
- 27 to 45 years: shared clinical decision-making, not routine.
- Two doses (0 and 6 to 12 months) if started before the 15th birthday; three doses if started at 15 or later or if immunocompromised.
- Vaccinated patients follow the same screening schedule.
The approach to an abnormal result
The 2019 ASCCP guidelines manage by risk: the test result plus prior history estimate the immediate risk of CIN3 or worse, and that risk sets the next step.
- HPV 16 or 18 positiveColposcopy, whatever the cytology shows.
- Other high-risk HPV types positiveReflex cytology on the same sample decides: normal cytology usually means repeat HPV testing in 1 year; ASC-US or worse means colposcopy.
- ASC-US with a negative HPV testRepeat HPV-based testing in 3 years.
- LSIL, or ASC-US that is HPV positiveColposcopy for most patients 25 and older.
- HSILColposcopy, or expedited excision (LEEP) without colposcopy in nonpregnant patients 25 or older when the risk is high, such as HSIL with HPV 16.
- Atypical glandular cellsColposcopy with endocervical sampling, plus endometrial sampling if 35 or older or at risk for endometrial cancer.
- CIN2 or CIN3 on biopsyExcision, usually LEEP. Observation is an option for CIN2 in patients concerned about future pregnancy.
Patients 21 to 24 are managed more conservatively: ASC-US or LSIL means repeat cytology in 1 year rather than colposcopy. In pregnancy, colposcopy is safe, endocervical curettage is avoided, and treatment of CIN waits until after delivery unless invasive cancer is suspected.
FIGO 2018 staging
| Stage | Extent | The detail that gets tested |
|---|---|---|
| IA1 | Microscopic, stromal invasion 3 mm or less | Lateral width no longer counts |
| IA2 | Stromal invasion more than 3 mm and up to 5 mm | Still microscopic |
| IB1 to IB3 | Confined to the cervix, split by size: 2 cm or less, 2 to 4 cm, more than 4 cm | IB3 is treated as locally advanced |
| IIA | Upper two-thirds of the vagina, no parametrial invasion | |
| IIB | Parametrial invasion, not to the pelvic wall | |
| IIIA to IIIB | Lower third of the vagina, or pelvic wall, or hydronephrosis or a nonfunctioning kidney | Hydronephrosis means at least IIIB |
| IIIC1 and IIIC2 | Pelvic or para-aortic lymph node metastasis | Imaging or pathology can assign it |
| IVA and IVB | Bladder or rectal mucosa, or distant metastasis |
In broad terms, early disease is treated surgically (conization or simple hysterectomy for IA1, radical hysterectomy with nodal assessment for small IB tumors), and locally advanced disease (IB3 and higher) with concurrent cisplatin-based chemoradiation and brachytherapy.
Clue in the stem, next best step
| Clue in the stem | What it points to | Next best step |
|---|---|---|
| 19-year-old, sexually active, asks for a Pap test | Below screening age | No cervical screening; offer HPV vaccine and STI testing |
| 26-year-old, normal cytology 3 years ago | Due for routine screening | Cytology (or primary HPV at 25 or older under ACS) |
| 35-year-old, primary HPV positive for HPV 16 | High immediate risk | Colposcopy |
| 40-year-old, HPV positive (not 16 or 18), reflex cytology normal | Lower risk | Repeat HPV testing in 1 year |
| 23-year-old with LSIL | Young patient, likely to clear | Repeat cytology in 1 year |
| Pregnant at 14 weeks with HSIL | Abnormal screen in pregnancy | Colposcopy without endocervical curettage; defer treatment unless cancer suspected |
| Cervical mass and new bilateral hydronephrosis | Pelvic wall or ureteral involvement | Stage at least IIIB; chemoradiation |
Where students lose points
- Screening a 19-year-old because she is sexually active, or adding HPV testing at 21 to 24.
- Repeating cytology for an HPV 16 positive result. It goes to colposcopy.
- Sending a 22-year-old with LSIL to colposcopy.
- Performing endocervical curettage, or treating CIN, during pregnancy.
- Stopping screening at 65 without confirming adequate prior negative results.
- Using the old 7 mm width criterion for stage IA. FIGO 2018 removed it.
- Telling a vaccinated patient she can skip screening.
Practice question
A 34-year-old woman, gravida 2, para 2, comes for a routine visit. Her last screening was 5 years ago with a negative primary HPV test. She has no symptoms. She uses a levonorgestrel IUD and has had one sexual partner for 8 years. Pelvic examination is normal. A clinician-collected primary HPV test is positive for HPV 16.
Which of the following is the most appropriate next step in management?
- Repeat HPV testing in 1 year
- Repeat HPV testing in 3 years
- Colposcopy
- Loop electrosurgical excision procedure
- Routine screening in 5 years
Show the answer
Answer: C. Under the 2019 ASCCP risk-based guidelines, a positive test for HPV 16 or 18 carries enough immediate risk of CIN3 or worse to require colposcopy, regardless of the cytology result.
Why the others are wrong. A and B: surveillance intervals apply to lower-risk results, such as HPV positivity for other types with normal cytology. D: expedited excision without colposcopy is reserved for very high-risk results, such as HSIL with HPV 16. E: a positive high-risk HPV result ends routine screening until it is worked up.
60-second recall
Say each answer out loud before you reveal it, then mark yourself. Retrieval, not rereading, is what makes it stick.
121 to 29
Cytology every 3 years.Did you get it?230 to 65
Primary HPV every 5 years preferred; self-collection is an option (repeat in 3 years after a negative self-collected test under ACS).Did you get it?3HPV 16 or 18 positive
Colposcopy.Did you get it?4Ages 21 to 24 with ASC-US or LSIL
Repeat cytology in 1 year.Did you get it?5HPV vaccine
Routine at 11 to 12, catch-up to 26, two doses if started before 15.Did you get it?6Hydronephrosis
Stage IIIB at least.Did you get it?
Make retrieval a habit on every topic with Learning to Learn Medicine. Module 1 is free; the full bundle (the course plus all 12 Recall Labs) is a one-time $199.
Next: browse every Board Review post, review endometrial cancer for the OB-GYN shelf, or see MedRise for students.
Sources
- Healio. ACOG updates cervical cancer screening guidance to include self-collection option. April 24, 2026
- American College of Obstetricians and Gynecologists. Cervical cancer screening guidance, 2026 (Guideline Central summary)
- Perkins RB, et al. Self-collected vaginal specimens for HPV testing and guidance on screening exit: an update to the American Cancer Society cervical cancer screening guideline. CA Cancer J Clin, 2026 (PubMed 41342729)
- US Preventive Services Task Force. Cervical cancer: screening (including the December 2024 draft update)
- Perkins RB, et al. 2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis, 2020 (PubMed 32243307)
- Meites E, et al. Human papillomavirus vaccination for adults: updated recommendations of the ACIP. MMWR, 2019 (PubMed 31415491)
- Bhatla N, et al. Revised FIGO staging for carcinoma of the cervix uteri. Int J Gynaecol Obstet, 2019 (PubMed 30656645)
MedRise Board Review is educational content for exam preparation only. It is not medical advice and does not replace current guidelines, your school's materials or clinical judgment.



